Survival outcome prediction is a challenging weakly-supervised and ordinal regression task in computational pathology that involves modeling complex interactions within the tumor microenvironment in ...

CHICAGO — In this video, Paolo F. Caimi, MD, MBA, discusses research evaluating whether multi-virus specific T-cells could enhance bispecific antibody activity in lymphoma. Caimi, staff ...

Sometimes, cats get into things. It’s going to happen, because every cat’s middle name is actually, legally, “accident.” They are drawn to things they shouldn’t be, and they’re often specifically ...

Media Contact: Kristen Ingram, (650) 467-6800 Advocacy Contact: Catherine Creme Henry, (202) 258-8228 Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, +41 61 687 5284 ...

Inconsistencies in the preparation of histology slides make it difficult to perform quantitative analysis on their results. In this paper we provide two mechanisms for overcoming many of the known ...

Key Takeaways SENTI-202, an off-the-shelf CAR NK cell therapy for AML, received FDA orphan drug designation, supporting its development for relapsed or refractory cases. LYL314, a CAR T-cell therapy ...

Session ID: 2025-07-02:4d5fa2e1d3ea57191fac9102 Player Element ID: V61ce242e_558c_447e_9107_acb9fd2d6e1d_6374466286112 ...

Lead author Yume Okamoto, a doctoral student, said of the research: “When we called for participants, we were moved to receive responses from 265 cat owners from across Japan in just a single day, and ...

Breyanzi Achieves High Overall Response Rate in R/R MZL. In the Phase II TRANSCEND FL trial, Breyanzi demonstrated a 95.5% overall response rate and a 62.1% complete response rate in patients with ...

One Gray Cat named Gracie has taken weird feline behavior a step further by turning into a dog and wagging her tail like a maniac the second she sees an intruder in her backyard — and this time, the ...

Breyanzi (liso-cel; lisocabtagene maraleucel) demonstrated high rates of durable responses and a consistent safety profile in patients with relapsed or refractory marginal zone lymphoma, according to ...

The phase 2 LuminICE-203 trial (NCT05883449) included 24 patients with relapsed/refractory Hodgkin lymphoma. 3 The patients had a median age of 42.5 years at baseline and had received a median of ...